Ausbiz Capital is now SureStone Capital. Same team, same ABN and AFS authorisations.

ASX: MYXMayne Pharma Group LimitedHealth Care

Mayne Pharma Agrees A$6.40 Cash Scheme With Gedeon Richter

Mayne Pharma entered a scheme deed for Gedeon Richter to acquire it at A$6.40 cash per share, valuing equity at about A$604 million, subject to approvals.

By Digifin Pty Ltd · About this coverage

Key Points

  • Gedeon Richter to acquire Mayne Pharma for A$6.40 cash per share by scheme
  • Values equity at approximately A$604 million, a 99.4% premium to the 16 November close
  • Board unanimously recommends the Scheme, subject to the Independent Expert and no Superior Proposal
  • Conditional on FIRB, Hart-Scott-Rodino, Court approval and the Evaris Pharma sale
  • Scheme Meeting expected in late January and implementation in March
Mayne Pharma Group Limited (ASX:MYX)

About Mayne Pharma (ASX:MYX)

Mayne Pharma Group Limited is an ASX-listed specialty pharmaceutical company headquartered in Adelaide. It commercialises dermatology and women's health medicines, primarily in the United States, and operates a direct-to-patient prescription distribution platform through its licensed pharmacy, Adelaide Apothecary. The company also provides contract development and manufacturing services to clients worldwide.

Mayne Pharma (ASX:MYX) has entered a Scheme Implementation Deed with Gedeon Richter Plc, under which Richter has agreed to acquire 100% of Mayne Pharma's shares for A$6.40 cash per share by scheme of arrangement.

The Scheme Consideration values Mayne Pharma's equity at approximately A$604 million, which the company calculates on about 94.4 million shares assuming its Convertible Notes convert at maturity. It represents a premium of 99.4% to the closing share price on 16 November 2026 and 124% to the 30-day VWAP. The Board unanimously recommends shareholders vote in favour, in the absence of a Superior Proposal and subject to the Independent Expert concluding that the Scheme is in their best interests. Funicular Funds (9.82%), Mr Bruce Mathieson (6.46%) and Trium Capital (5.85%), together holding 22.14%, have each said they intend to vote in favour absent a Superior Proposal. Richter will fund the acquisition from internal cash resources and there is no financing condition. Conditions include Foreign Investment Review Board and Hart-Scott-Rodino approvals, shareholder and Court approval, and completion of the sale of the International business to Evaris Pharma, which is itself subject to ACCC approval. The parties will also file a voluntary CFIUS declaration. The Scheme Meeting is expected in late January and implementation in March.

The timetable is indicative. Regulatory approvals, the Independent Expert's report, shareholder and Court approval, and the International business sale are all outstanding. Break fee terms are left to the attached deed.

Back to all ASX Company News

Source: Mayne Pharma Group Limited (ASX:MYX), 17 November 2026. Summary content supplied by Digifin Pty Ltd.

News summary only, not financial advice. It does not consider your objectives, financial situation or needs.

Tuesday, 17 November 2026

Also summarised today

All ASX Company News
ASX: 29MMaterials

29Metals Wins Preliminary Capricorn Copper Tailings Approval

29Metals received preliminary approval for a new tailings facility at Capricorn Copper, a key restart step, while EPBC approval and restart funding remain open.

17 Nov, 8:25 am AEDT
ASX: CATInformation Technology

Catapult 1H FY27 ACV Up 25% to US$145.2M, Margin at 20%

Catapult's 1H FY27 Annualized Contract Value rose 25% (CC) to US$145.2M and Management EBITDA reached US$16.1M at a 20% margin, with no numerical FY27 guidance.

17 Nov, 8:40 am AEDT
ASX: DLIMaterials

Delta Lithium Mt Ida Scoping Study Models $748M NPV

Delta Lithium's Mt Ida Scoping Study models a post-tax NPV of $748M and IRR of 33% on $483M pre-production capital, at +/- 40% accuracy with funding needed.

17 Nov, 9:36 am AEDT
ASX: LRVMaterials

Larvotto Ships First Hillgrove Gold Concentrate to Glencore

Larvotto despatched its first gold concentrate from Hillgrove to offtake partner Glencore, after antimony in October, with first gold doré due in late November.

17 Nov, 9:34 am AEDT
ASX: LYLIndustrials

Lycopodium Wins A$31.1m Assafou Construction Management Role

Lycopodium won a construction management contract worth about A$31.1 million at Endeavour Mining's Assafou project, taking total work there to A$74.0 million.

17 Nov, 8:31 am AEDT
ASX: MEZUtilities

Meridian Hydro Storage at 128% as Retail Volumes Fall 8.3%

Meridian Energy's October 2026 report shows national hydro storage at 128% of average by 9 November, while retail sales volumes fell 8.3% on October 2025.

17 Nov, 7:30 am AEDT
ASX: PDIMaterials

PDI Gold Granted Bankan and Mansounia Exploitation Permits

Guinea granted PDI Gold Exploitation Permits for Bankan and Mansounia, with Bankan's first gold expected in mid-2028 and no rise to US$463m capital expected.

17 Nov, 9:26 am AEDT
ASX: PRNMaterials

Perenti Wins Circa A$1 Billion Geita Underground Contract

Perenti's AUMS won a new five-year underground mining contract at AngloGold Ashanti's Geita Gold Mine in Tanzania with an estimated value of about A$1 billion.

17 Nov, 8:56 am AEDT
ASX: TNEInformation Technology

TechnologyOne FY26 Profit Before Tax Up 20% to $217.6m

TechnologyOne's FY26 profit before tax rose 20% to $217.6 million, top of upgraded guidance, with ARR up 18% to $652.1 million and a 32.5c final dividend.

17 Nov, 8:58 am AEDT

Announcement summaries are published each trading day. General advice only.

Copyright © 2026 SureStone Capital